Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Gross Profit (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Gross Profit for 5 consecutive years, with $6.4 million as the latest value for Q1 2025.

  • Quarterly Gross Profit rose 35.82% to $6.4 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, down 72.19% year-over-year, with the annual reading at $6.4 million for FY2025, 72.19% down from the prior year.
  • Gross Profit for Q1 2025 was $6.4 million at Whitehawk Therapeutics, down from $6.4 million in the prior quarter.
  • The five-year high for Gross Profit was $14.0 million in Q4 2021, with the low at $2.1 million in Q1 2022.
  • Average Gross Profit over 5 years is $5.6 million, with a median of $5.4 million recorded in 2023.
  • The sharpest move saw Gross Profit tumbled 64.25% in 2022, then skyrocketed 150.85% in 2023.
  • Over 5 years, Gross Profit stood at $14.0 million in 2021, then crashed by 64.25% to $5.0 million in 2022, then rose by 7.87% to $5.4 million in 2023, then grew by 19.45% to $6.4 million in 2024, then decreased by 0.99% to $6.4 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $6.4 million, $6.4 million, and $6.4 million for Q1 2025, Q4 2024, and Q3 2024 respectively.